Document Detail

Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
MedLine Citation:
PMID:  15757608     Owner:  NLM     Status:  MEDLINE    
Thirty-six consecutive patients in New York Heart Association functional class IV, who were resistant to 24-hour continuous dobutamine infusion, were treated with continuous infusions of dobutamine 10 microg/kg/min for > or =48 hours (group I, n = 18), followed by weekly intermittent 8-hour infusions or more often if needed. In group II (n = 18), after the initial 24-hour infusion of dobutamine, a 24-hour levosimendan infusion was added followed by biweekly 24-hour infusions. The addition of intermittent levosimendan infusions prolonged the survival of patients with advanced heart failure refractory to intermittent dobutamine infusions (45-day survival rates were 6% and 61% in groups I and II, respectively; p = 0.0002, log-rank test).
John N Nanas; Panagiotis Papazoglou; Eleftheria P Tsagalou; Argirios Ntalianis; Elias Tsolakis; John V Terrovitis; John Kanakakis; Seraphim N Nanas; George P Alexopoulos; Maria I Anastasiou-Nana
Related Documents :
7930248 - Transesophageal dobutamine stress echocardiography for evaluation of patients with coro...
1396808 - Pharmacological stress echocardiography in the diagnosis of coronary artery disease and...
16516088 - Predictive value of normal left atrial volume in stress echocardiography.
11250968 - Incremental prognostic value of stress echocardiography as an adjunct to exercise elect...
10496458 - Qt interval and qt dispersion in endurance athletes and in power athletes using large d...
22492358 - Not just inductive: a crucial mechanical role for the endoderm during heart tube assembly.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  95     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-10     Completed Date:  2005-04-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  768-71     Citation Subset:  AIM; IM    
University of Athens School of Medicine, Department of Clinical Therapeutics, "Alexandra" Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiotonic Agents / administration & dosage*,  adverse effects
Chronic Disease
Dobutamine / administration & dosage*,  adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance
Drug Therapy, Combination
Exercise Test / drug effects
Heart Failure / drug therapy*,  mortality
Hemodynamics / drug effects
Hydrazones / administration & dosage*,  adverse effects
Infusions, Intravenous
Middle Aged
Multivariate Analysis
Pyridazines / administration & dosage*,  adverse effects
Radionuclide Ventriculography
Survival Rate
Reg. No./Substance:
0/Cardiotonic Agents; 0/Hydrazones; 0/Pyridazines; 131741-08-7/simendan; 34368-04-2/Dobutamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of...
Next Document:  Effect of chronic right ventricular apical pacing on left ventricular function.